Browsing Tag
Merck
96 posts
Merck advances pimicotinib in China as Center for Drug Evaluation accepts TGCT marketing application following pivotal Phase 3 data
Merck’s TGCT treatment pimicotinib moves closer to approval in China after CDE accepts marketing application; global filings planned next.
Merck (NASDAQ: MRK) wins FDA approval for ENFLONSIA to prevent RSV in infants
FDA clears Merck’s ENFLONSIA (NASDAQ: MRK) for RSV prevention in infants. See trial data, stock reaction, pediatric market impact & analyst projections.
Merck’s enlicitide shows major LDL-C reduction in Phase 3 trials, raising hopes for first oral PCSK9 approval
Merck’s enlicitide hits key milestones in Phase 3 trials, bringing the first oral PCSK9 inhibitor closer to market. Will this reshape LDL-C treatment?
Merus N.V. stock soars on breakthrough cancer trial: What drove MRUS to the top gainers list?
Merus N.V. stock jumped 32% on breakthrough cancer trial data. Find out what’s driving MRUS and what could come next for this biotech leader.
Neuphoria Therapeutics secures milestone payment from Merck as Alzheimer’s clinical trial advances
Neuphoria Therapeutics Inc. (Nasdaq: NEUP), a late-stage biotechnology company focused on developing treatments for neuropsychiatric disorders, has announced…
Merck initiates Phase 3 waveLINE-010 trial for zilovertamab vedotin in diffuse large B-cell lymphoma
Merck, known as MSD outside the United States and Canada, has launched its pivotal Phase 3 waveLINE-010 clinical…
Merck invests $50m in Personalis to bolster Moderna collaboration on individualized cancer therapies
Personalis, Inc., a leader in precision oncology solutions, has secured a significant investment from Merck and extended its…
Merck’s WELIREG receives positive CHMP opinion for VHL tumours and advanced RCC
Merck, known as MSD outside the U.S. and Canada, has moved a step closer to offering innovative treatment…
Merck licenses innovative anti-cancer therapy LM-299 from LaNova Medicines
In a strategic move to broaden its oncology portfolio, Merck & Co., Inc. (NYSE: MRK), recognized globally as…
Merck’s $1.3bn bet on cancer therapy: Inside the Modifi Biosciences acquisition
Merck & Co., a global leader in pharmaceuticals, has acquired Modifi Biosciences, a cutting-edge biotech startup based in…